IDEXX Laboratories Q1 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: Increased 14% year-over-year to $1.19 billion, with organic growth of 11%.

CAG Diagnostics Recurring Revenue: Grew 11% organically, with U.S. growth at nearly 11% and international growth at approximately 12%.

Operating Margin: Improved by 100 basis points to 32.1%, supported by gross margin expansion to 63.4%.

Earnings Per Share (EPS): Reported at $3.47, reflecting a 15% increase on a comparable basis.

Free Cash Flow: $234 million for the quarter, maintaining a conversion rate of 99% on a trailing 12-month basis.

Share Repurchases: $361 million allocated, reducing diluted shares outstanding by 2.1%.

2Strategic Updates and Business Highlights

IDEXX reported strong performance in its companion animal business, driven by innovations and increased diagnostics utilization.

Instrument placements saw a 28% organic growth, with 1,100 IDEXX inVue Dx analyzers placed in Q1.

The company launched new products, including the Cancer DX platform, which is gaining traction in both diagnostics and screening workflows.

IDEXX's international markets showed robust growth, attributed to long-term investments in commercial execution and localized solutions.

The company is advancing its AI capabilities, particularly in the inVue Dx platform, which is expected to enhance diagnostics and customer engagement.

3Forward Guidance and Outlook

Revenue Guidance: Increased for the full year to a range of $4.675 billion to $4.76 billion, reflecting an overall growth of 8.6% to 10.6%.

Organic Revenue Growth: Updated outlook of 7.7% to 9.7%, with CAG Diagnostics recurring revenue growth projected at 8.7% to 10.7%.

EPS Guidance: Revised to $14.45 to $14.90 per share, reflecting an increase of $0.13 at midpoint.

Second Quarter Expectations: Anticipated reported revenue growth of 7.3% to 9.3%, with organic growth of 6.7% to 8.7%.

4Bad News, Challenges, or Points of Concern

Clinical Visits: U.S. same-store clinical visits declined by approximately 1%, with expectations for a full-year decline of 1.5%, primarily affecting wellness visits.

Market Headwinds: Continued pressure from macroeconomic factors affecting discretionary spending and wellness visits.

Supply Chain Issues: Noted disruptions in the Water business, particularly in the Middle East, which could impact future growth.

Competitive Pressures: The need to maintain innovation and customer engagement to fend off competition in the diagnostics space.

5Notable Q&A Insights

InVue Dx Performance: Confidence remains high in achieving the annual target of 5,500 placements despite a slower start in Q1, attributed to customer mix dynamics.

Visit Dynamics: Positive trends in non-well visits are linked to an aging pet population and pent-up demand, though wellness visits remain under pressure.

International Growth: Strong performance in international markets is attributed to IDEXX's long-term investments and tailored solutions for local markets.

F&A Rollout: The controlled launch of the Fine Needle Aspiration (F&A) platform is on track, with plans for broader rollout later in the year, expected to enhance diagnostic capabilities significantly. This summary encapsulates the key points from the earnings call, providing a clear overview of IDEXX's financial performance, strategic direction, and outlook amidst challenges.